Last update Dec. 4, 2020
Carboprost is a synthetic prostaglandin similar to prostaglandin F2 alpha (dinoprostone). It induces the contractility of the uterine smooth muscles. It is administered intramuscularly in postpartum hemorrhages due to uterine atony when other drugs have not been effective.
Since the last update we have not found published data on its excretion in breastmilk.
Its very rapid elimination and its very low concentration in plasma (high intramuscular doses only produce concentrations of picograms in plasma: Pfizer 2014) make it very unlikely that significant quantities will transfer into breastmilk.
It has been widely used in obstetrics without encountering problems in breastfeeding babies.
Several experts consider its use during breastfeeding to be probably compatible. (Hale 2019, Briggs 2017).
We do not have alternatives for Carboprost Trometamol.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM